Europe
FDA accepts study protocol, providing green light for GENFIT to initiate Phase 2 clinical trial in pediatric NASH
Persons with Alzheimer’s disease have approximately 30% higher risk of head injuries, and 50% higher risk of traumatic brain injuries than persons without Alzheimer’s disease, a recent study from University of Eastern Finland shows.
Board Authorizes $6 Billion for Share Repurchases
Tecentriq is a monoclonal antibody that binds with the PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells. It blocks interactions with both PD-1 and B7.1 receptors.
The company’s proprietary CRISPR-Cas tech platform is used to selectively and precisely eradicate target bacterial, but still leave the patient’s microbial community alone.
Axovant has been busy, releasing interim results from two different clinical trials, one for Tay-Sachs, the other for Parkinson’s disease.
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion
March 8, 2019, United Kingdom, 2019- GHP Magazine has announced the winners of the 2019 Biotechnology Awards.
Kent medical device manufacturer receives a manufacturing accolade in the GHP Biotechnology Awards
The next couple of weeks look to be busy for the FDA, with a string of target action dates scheduled. This week marks three scheduled approvals, two for extra indications for already-approved biologics, and the third for a combination treatment for glaucoma. Here’s a look.
PRESS RELEASES